ENFN · Enfusion, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $51.17M | $49.45M | $48.05M | - | $44.36M | $42.72M | $40.97M | - | $39.15M |
| Cost of Revenue | - | $16.34M | $15.96M | $16.17M | - | $14.51M | $14.21M | $13.30M | - | $11.97M |
| Gross Profit | - | $34.83M | $33.49M | $31.88M | - | $29.85M | $28.51M | $27.67M | - | $27.18M |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | $18.78M | $18.67M | $20.22M | - | $16.72M | $16.33M | $14.47M | - | $13.09M |
| Total Operating Expenses | - | $31.84M | $30.79M | $32.99M | - | $27.16M | $26.07M | $22.99M | - | $24.24M |
| D&A | - | $1.30M | $1.10M | $2.67M | - | $892.0K | $915.0K | $1.87M | - | $892.0K |
| Operating Income | - | $2.98M | $2.70M | ($1.11M) | - | $2.69M | $2.45M | $4.68M | - | $4.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | $4.0K |
| Income Tax | - | $904.0K | $401.0K | ($117.0K) | - | $367.0K | $188.0K | $396.0K | - | $154.0K |
| Net Income | - | $1.42M | $1.83M | ($539.0K) | - | $1.83M | $629.0K | $2.94M | - | $3.29M |
| EPS - Basic | - | $0.02 | $0.02 | ($0.01) | - | $0.02 | $0.01 | $0.04 | - | $0.02 |
| EPS - Diluted | - | $0.02 | $0.02 | ($0.01) | - | $0.02 | $0.01 | $0.04 | - | $0.02 |
Balance Sheet
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $54.48M | $48.30M | $34.45M | $32.89M | $35.60M | $31.65M | $27.77M | $54.60M | $62.55M | $63.54M |
| Accounts Receivable | $31.99M | $32.17M | $33.67M | $30.93M | $28.07M | $24.86M | $25.17M | $24.36M | $25.86M | $28.99M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $867.0K | $1.18M | $816.0K | $3.36M | $2.21M | $1.34M | $868.0K | $1.29M | $1.69M | $1.19M |
| Current Assets | $93.52M | $85.44M | $74.17M | $70.92M | $69.85M | $62.05M | $59.63M | $86.65M | $96.81M | $96.03M |
| Total Assets | $143.26M | $134.94M | $120.09M | $110.96M | $108.97M | $101.74M | $94.05M | $121.49M | $123.78M | $115.60M |
| Current Liabilities | $27.34M | $23.57M | $17.87M | $17.41M | $20.31M | $16.37M | $13.76M | $13.71M | $17.38M | $11.99M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $43.72M | $38.76M | $30.68M | $28.34M | $31.49M | $28.46M | $21.81M | $22.35M | $20.34M | $12.43M |
| Stockholders' Equity | $73.22M | $69.92M | $64.30M | $58.05M | $53.67M | $50.73M | $48.13M | $63.70M | $65.01M | $61.13M |
| Retained Earnings | ($170.11M) | ($170.23M) | ($171.65M) | ($173.47M) | ($172.93M) | ($173.56M) | ($175.38M) | ($176.01M) | ($178.86M) | ($179.36M) |
Cash Flow
| Line item | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | $1.53M | - | - | - | $924.0K | - | - |
| Investing Cash Flow | - | - | - | ($2.75M) | - | - | - | ($2.55M) | - | - |
| Financing Cash Flow | - | - | - | ($1.37M) | - | - | - | ($6.35M) | - | - |
| CapEx | - | - | - | $635.0K | - | - | - | $2.55M | - | - |
| Free Cash Flow | - | - | - | $898.0K | - | - | - | ($1.63M) | - | - |
Ratios
| Metric | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 68.1% | 67.7% | 66.3% | - | 67.3% | 66.7% | 67.5% | - | 69.4% |
| Operating margin | - | 5.8% | 5.5% | -2.3% | - | 6.1% | 5.7% | 11.4% | - | 12.5% |
| EBITDA margin | - | 8.4% | 7.7% | 3.2% | - | 8.1% | 7.9% | 16.0% | - | 14.8% |
| Net margin | - | 2.8% | 3.7% | -1.1% | - | 4.1% | 1.5% | 7.2% | - | 8.4% |
| Free cash flow margin | - | - | - | 1.9% | - | - | - | -4.0% | - | - |
| FCF / Net income | - | - | - | -1.67 | - | - | - | -0.55 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | 36.7% | 37.8% | 42.1% | - | 37.7% | 38.2% | 35.3% | - | 33.4% |
| Effective tax rate | - | 39.0% | 18.0% | - | - | 16.7% | 23.0% | 11.9% | - | 4.5% |
| Return on assets | - | 1.0% | 1.5% | -0.5% | - | 1.8% | 0.7% | 2.4% | - | 2.8% |
| Return on equity | - | 2.0% | 2.8% | -0.9% | - | 3.6% | 1.3% | 4.6% | - | 5.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.42 | 3.62 | 4.15 | 4.07 | 3.44 | 3.79 | 4.33 | 6.32 | 5.57 | 8.01 |
| Quick ratio | 3.42 | 3.62 | 4.15 | 4.07 | 3.44 | 3.79 | 4.33 | 6.32 | 5.57 | 8.01 |
| Cash ratio | 1.99 | 2.05 | 1.93 | 1.89 | 1.75 | 1.93 | 2.02 | 3.98 | 3.60 | 5.30 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | 1225.8x |
| Equity multiplier | 1.96 | 1.93 | 1.87 | 1.91 | 2.03 | 2.01 | 1.95 | 1.91 | 1.90 | 1.89 |
| Liabilities / Assets | 0.31 | 0.29 | 0.26 | 0.26 | 0.29 | 0.28 | 0.23 | 0.18 | 0.16 | 0.11 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.38 | 0.41 | 0.43 | - | 0.44 | 0.45 | 0.34 | - | 0.34 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | 230d | 249d | 235d | - | 205d | 215d | 217d | - | 270d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | 26d | 19d | 76d | - | 34d | 22d | 35d | - | 36d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 15.4% | 15.8% | 17.3% | - | 13.3% | 16.9% | 68.2% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | 16.7% | 17.5% | 15.2% | - | 9.8% | 11.0% | 19.5% | - | - |
| Operating income growth (YoY) | - | 10.9% | 10.5% | - | - | -45.2% | - | -19.4% | - | - |
| Net income growth (YoY) | - | -22.6% | 190.3% | - | - | -44.5% | - | - | - | - |
| EPS growth (YoY) | - | 0.0% | 100.0% | - | - | 0.0% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | -2.6% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 36.4% | 37.8% | 33.6% | -8.9% | -17.4% | -17.0% | -18.6% | 16.1% | 17.6% | 6112800.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$201.61M totalPlatform Subscriptions$187.52M · 93.0%
Managed Services$12.69M · 6.3%
Other Services$1.40M · 0.7%
Geographic
$324.01M totalAmericas$125.80M · 38.8%
US$122.40M · 37.8%
Asia Pacific$43.46M · 13.4%
EMEA$32.35M · 10.0%
Peer comparison
Same SIC group: Services-Prepackaged Software
Comparing Enfusion against the 5 most active filers in the same SIC group.